SchizoWizard
$TNYA while we're all sitting in q4 catalyst purgatory, I found some relatively recent patents published by the company that are pretty interesting.
WO2026156172A2 — Biomarkers in arrhythmogenic right ventricular cardiomyopathy and methods of treatment
WO2026165422A1 - RBM20 Gene Editing Systems and Methods of Use
Tldr: they are coming up with ways to measure TN-401 efficacy in patients not experiencing symptoms of ARVC but have the gene deficiency, and Faraz isn't kidding when he said the company was doing gene editing too.
Now let's hope they figure out how to fund it all ...
20
